Predictive factors for the development of leukemia in patients with transient abnormal myelopoiesis and Down syndrome-Reference-Cited by-同舟云学术

Predictive factors for the development of leukemia in patients with transient abnormal myelopoiesis and Down syndrome

Published:2021-03-03 Issue:5 Volume:35 Page:1480-1484
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Yamato Genki,Deguchi Takao,Terui Kiminori,Toki Tsutomu^ORCID,Watanabe Tomoyuki,Imaizumi Takahiro,Hama Asahito^ORCID,Iwamoto Shotaro^ORCID,Hasegawa Daisuke,Ueda Takahiro,Yokosuka Tomoko,Tanaka Shiro,Yanagisawa Ryu,Koh Katsuyoshi,Saito Akiko M.,Horibe Keizo,Hayashi Yasuhide,Adachi Souichi,Mizutani Shuki,Taga Takashi^ORCID,Ito Etsuro,Watanabe Kenichiro,Muramatsu Hideki^ORCID

Funder

Japan Agency for Medical Research and Development

Health and Labor Sciences Research Grants

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-021-01171-y.pdf

Reference15 articles.

1. Langebrake C, Creutzig U, Reinhardt D. Immunophenotype of down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts. Klin Padiatr. 2005;217:126–34.

2. Pine SR, Guo Q, Yin C, Jayabose S, Druschel CM, Sandoval C. Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome. Blood. 2007;110:2128–31.